Jazz Pharmaceuticals (JAZZ) Invested Capital (2010 - 2026)
Jazz Pharmaceuticals' quarterly Invested Capital came in at $9.9 billion in Q1 2026, up 3.61% year-on-year from $9.5 billion in Q1 2025, and up 2.17% quarter-over-quarter from $9.7 billion in Q4 2025.
Jazz Pharmaceuticals has reported Invested Capital for 17 years, with the latest figure at $9.9 billion in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital rose 3.61% year-over-year to $9.9 billion; the trailing twelve-month figure through Mar 2026 stood at $9.9 billion (up 3.61% YoY), and the FY2025 full-year result was $9.7 billion, down 5.15% from the prior year.
- Invested Capital for Q1 2026 stood at $9.9 billion, up from $9.7 billion in the prior quarter.
- The five-year high for Invested Capital was $10.3 billion in Q3 2024, with the low at $8.5 billion in Q3 2022.
- Average Invested Capital over 5 years is $9.4 billion, with a median of $9.4 billion recorded in 2024.
- Peak annual rise in Invested Capital reached 63.28% in 2022, while the deepest fall reached 17.08% in 2022.
- Tracing JAZZ's Invested Capital over 5 years: stood at $8.8 billion in 2022, then rose by 7.26% to $9.4 billion in 2023, then grew by 7.96% to $10.2 billion in 2024, then fell by 5.15% to $9.7 billion in 2025, then grew by 2.17% to $9.9 billion in 2026.
- The last three Invested Capital figures came in at $9.9 billion (Q1 2026), $9.7 billion (Q4 2025), and $9.3 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Jazz Pharmaceuticals | 14.35 Bn | 12.51 Bn | 934.80 Mn | 9.89 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.89 Bn |
| Dec 31, 2025 | 9.68 Bn |
| Sep 30, 2025 | 9.32 Bn |
| Jun 30, 2025 | 9.07 Bn |
| Mar 31, 2025 | 9.54 Bn |
| Dec 31, 2024 | 10.20 Bn |
| Sep 30, 2024 | 10.28 Bn |
| Jun 30, 2024 | 9.47 Bn |
| Mar 31, 2024 | 9.41 Bn |
| Dec 31, 2023 | 9.45 Bn |
| Sep 30, 2023 | 9.20 Bn |
| Jun 30, 2023 | 9.24 Bn |
| Mar 31, 2023 | 9.06 Bn |
| Dec 31, 2022 | 8.81 Bn |
| Sep 30, 2022 | 8.47 Bn |
| Jun 30, 2022 | 9.22 Bn |
| Mar 31, 2022 | 9.63 Bn |
| Dec 31, 2021 | 10.02 Bn |
| Sep 30, 2021 | 10.22 Bn |
| Jun 30, 2021 | 10.87 Bn |
| Mar 31, 2021 | 5.90 Bn |
| Dec 31, 2020 | 5.75 Bn |
| Sep 30, 2020 | 5.46 Bn |
| Jun 30, 2020 | 5.24 Bn |
| Mar 31, 2020 | 4.42 Bn |
| Dec 31, 2019 | 4.72 Bn |
| Sep 30, 2019 | 4.66 Bn |
| Jun 30, 2019 | 4.58 Bn |
| Mar 31, 2019 | 4.33 Bn |
| Dec 31, 2018 | 4.35 Bn |
| Sep 30, 2018 | 4.62 Bn |
| Jun 30, 2018 | 4.46 Bn |
| Mar 31, 2018 | 4.37 Bn |
| Dec 31, 2017 | 4.29 Bn |
| Sep 30, 2017 | 4.05 Bn |
| Jun 30, 2017 | 3.87 Bn |
| Mar 31, 2017 | 3.86 Bn |
| Dec 31, 2016 | 3.91 Bn |
| Sep 30, 2016 | 4.01 Bn |
| Jun 30, 2016 | 2.98 Bn |
| Mar 31, 2016 | 2.89 Bn |
| Dec 31, 2015 | 2.89 Bn |
| Sep 30, 2015 | 2.85 Bn |
| Jun 30, 2015 | 2.81 Bn |
| Mar 31, 2015 | 2.65 Bn |
| Dec 31, 2014 | 2.71 Bn |
| Sep 30, 2014 | 2.68 Bn |
| Jun 30, 2014 | 2.48 Bn |
| Mar 31, 2014 | 2.47 Bn |
| Dec 31, 2013 | 1.85 Bn |
| Sep 30, 2013 | 1.80 Bn |
| Jun 30, 2013 | 1.73 Bn |
| Mar 31, 2013 | 1.19 Bn |
| Dec 31, 2012 | 1.58 Bn |
| Sep 30, 2012 | 912.81 Mn |
| Jun 30, 2012 | 855.21 Mn |
| Mar 31, 2012 | 781.83 Mn |
| Dec 31, 2011 | 192.79 Mn |
| Sep 30, 2011 | 141.33 Mn |
| Jun 30, 2011 | 105.60 Mn |
| Dec 31, 2010 | 37.90 Mn |